516 patents
Page 16 of 26
Utility
Salts of 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YL-METHYL)- IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-YL]BENZAMIDE and Processes Related to Preparing the Same
6 May 21
The present invention is directed to dihydrochloric acid and dibenzenesulfonic acid salts of the c-Met kinase inhibitor 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and pharmaceutical compositions thereof, useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
Lingkai Weng, Lei Qiao, Jiacheng Zhou, Pingli Liu, Yongchun Pan
Filed: 8 Sep 20
Utility
Biomarkers for Graft-versus-host Disease
29 Apr 21
Biomarkers are provided that are predictive of a subject's responsiveness to a JAK inhibitor.
Michael D. Howell, Sherry Owens, Michael A. Pratta
Filed: 8 Oct 20
Utility
Biomarkers for Graft-versus-host Disease
29 Apr 21
Biomarkers are provided that are predictive of a subject's responsiveness to a JAK inhibitor.
Michael D. Howell, Sherry Owens, Michael A. Pratta
Filed: 8 Oct 20
Utility
Use of JAK1 Inhibitors for the Treatment of Cutaneous Lupus Erythematosus and Lichen Planus (LP)
22 Apr 21
The present application provides methods of treating a disease selected from cutaneous lupus erythematosus (CLE) and Lichen planus (LP) in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a JAK1 selective inhibitor, or a pharmaceutically acceptable salt thereof.
Paul Smith, Jörg Wenzel
Filed: 16 Oct 20
Utility
Heterocyclic Compounds As Immunomodulators
22 Apr 21
Zhiyong Yu, Liangxing Wu, Wenqing Yao
Filed: 30 Dec 20
Utility
Bicyclic Heterocycles As FGFR Inhibitors
22 Apr 21
Artem Shvartsbart, Jeremy Roach, Wenqing Yao
Filed: 15 Oct 20
Utility
Heterocyclic Compounds As Immunomodulators
22 Apr 21
Liangxing Wu, Kaijiong Xiao, Wenqing Yao
Filed: 29 Dec 20
Utility
Advanced gaming visualization system
13 Apr 21
A monocular unit permits visualization of image data received from an imaging device associated with a mobile computing device.
Ivan Arbouzov
Filed: 12 Jun 19
Utility
Process for preparing a composition comprising an enantiomeric excess of greater than or equal to 90% of the (R)-enantiomer of a compound of formula III
13 Apr 21
Jiacheng Zhou, James D. Rodgers, Haisheng Wang
Filed: 10 Jun 19
Utility
Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors
13 Apr 21
Andrew W. Buesking, Richard B. Sparks, Andrew P. Combs, Brent Douty, Nikoo Falahatpisheh, Lixin Shao, Stacey Shepard, Eddy W. Yue, Artem Shvartsbart, David M. Burns, Daniel Levy
Filed: 2 Oct 19
Utility
Salts of an LSD1 inhibitor and processes for preparing the same
6 Apr 21
The present invention relates to processes and intermediates for preparing 3-(cyanomethyl)-3-(4-{[(1R,2S)-2-phenylcyclopropyl]amino}piperidin-1-yl)azetidine-1-sulfonamide, and salts and solid forms thereof, which selectively modulate demethylase.
Zhongjiang Jia, Wayne Han, Yongchun Pan, Timothy Martin, Jiacheng Zhou, Qun Li
Filed: 29 Aug 19
Utility
Substituted [1,2,4]triazolo[1,5-a]pyrazines as LSD1 inhibitors
6 Apr 21
Liangxing Wu, Xiaozhao Wang, Wenqing Yao, Colin Zhang
Filed: 3 Oct 19
Utility
Carboxamide Compounds and Uses Thereof
1 Apr 21
Oleg Vechorkin, Jun Pan, Alexander Sokolsky, Evan Styduhar, Qinda Ye, Wenqing Yao
Filed: 9 Sep 20
Utility
Bicyclic Heterocycles As FGFR Inhibitors
1 Apr 21
Oleg Vechorkin, Hai Fen Ye, Wenqing Yao
Filed: 30 Sep 20
Utility
PYRIDO[3,2-D]PYRIMIDINE Compounds As Immunomodulators
1 Apr 21
Jingwei Li, Liangxing Wu, Wenqing Yao
Filed: 29 Sep 20
Utility
Treatment of B-cell Malignancies by a Combination Jak and PI3K Inhibitors
1 Apr 21
This invention relates to methods of treating B-cell malignancies using a combination of inhibitors of JAK1 and/or JAK2 and inhibitors of PI3Kδ.
Peggy A. Scherle, Xuesong Liu
Filed: 12 May 20
Utility
Amorphous Solid Form of a Bet Protein Inhibitor
18 Mar 21
The present invention relates to an amorphous solid form of (4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one, and processes for its preparation, which is an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and is useful in the treatment of various diseases such as cancer.
Shili Chen, William Frietze, Zhongjiang Jia, Pingli Liu, Jiacheng Zhou
Filed: 19 Nov 20
Utility
Tricyclic heterocyclic compounds as sting activators
16 Mar 21
The present application provides tricyclic heterocyclic compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
Liangxing Wu, Neil Lajkiewicz, Yingda Ye, Zhenwu Li, Wenqing Yao
Filed: 24 May 19
Utility
Bicyclic heterocycles as FGFR inhibitors
16 Mar 21
The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
Yaping Sun, Wenqing Yao, Liangxing Wu, Meizhong Xu, Ding-Quan Qian, Fenglei Zhang
Filed: 10 Sep 19
Utility
JAK1 Inhibitors for the Treatment of Myelodysplastic Syndromes
11 Mar 21
This invention relates to JAK1 selective inhibitors, particularly pyrrolo[2,3-d]pyrimidine and pyrrolo[2,3-b]pyridine derivatives, and their use in treating myelodysplastic syndromes (MDS).
Krishna Vaddi
Filed: 3 Apr 20